Search Tag: #ESCcongress
#ESCCongress: AI Algorithm for Prevention of Cardiovascular Disease
2022 29 Aug
Late-breaking research presented at the ESC Congress shows that an artificial intelligence (AI) algorithm accurately estimates the risk of heart disease caused by cumulative exposure to cholesterol and blood pressure levels and the benefits of lowering both, thus providing the information needed to make individual treatment decisions. Atherosclerotic... Read more
#ESCCongress: Atrial Fibrillation Screening Using Smartphones
2022 29 Aug
The latest research presented at the ESC Congress in Barcelona shows that conventional smartphone-assisted atrial fibrillation (AF) screening more than doubles the detection and treatment rate in older people compared to routine screening. AF is the most common heart rhythm disorder and affects over 40 million people worldwide. People with this... Read more
#ESCCongress: Mortality Benefits With High-Dose Influenza Vaccines
2022 27 Aug
Findings from the DANFLU-1 trial presented at the ESC Congress in Barcelona show that high-dose influenza vaccination in older adults reduces the risk of death by 49% and the incidence of hospitalisation for influenza or pneumonia by 64% compared with standard-dose vaccination. Several studies have previously investigated the association between... Read more
#ESCCongress: PERSPECTIVE Trial - Sacubitril/Valsartan and Cognitive Function
2022 27 Aug
The latest findings from the PERSPECTIVE trial were presented at the ESC Congress in Barcelona. The study aimed to evaluate sacubitril/valsartan compared with valsartan among symptomatic heart failure patients. The study included 592 patients with symptomatic heart failure. Two hundred and ninety-five patients received 97/103 mg sacubitril/valsartan,... Read more
#ESCCongress: PRONOUNCE Trial - Safety of ADT Remains Unresolved
2021 30 Aug
Late-breaking research from the PRONOUNCE trial was presented in a Hot Line session at ESC Congress 2021. The cardiovascular safety of androgen deprivation therapy (ADT) for prostate cancer remains unresolved after the trial was terminated early. Every year, approximately one million men are diagnosed with prostate cancer worldwide. These patients... Read more
#ESCCongress: ENVISAGE-TAVI AF Trial
2021 28 Aug
In another Hot Line session at the ESC Congress 2021, findings from the ENVISAGE-TAVI AF showed that edoxaban is non-inferior to warfarin and its analogues for adverse clinical events in patients with atrial fibrillation after transcatheter aortic valve implantation. The prevalence of pre-existing or new-onset atrial fibrillation after TAVI ranges... Read more
#ESCCongress: Results of the EMPEROR-Preserved Trial
2021 27 Aug
In a Hot Line Session at the ESC Congress 2021, the results of the EMPEROR-Preserved trial were presented that demonstrated a significant reduction in composite cardiovascular endpoints in patients with heart failure and preserved ejection fraction. This was a pooled analysis of two randomised trials that investigated the beneficial effects of... Read more
#ESCCongress: Results from VANISH and DAPA-HF
2021 27 Aug
At the ESC Congress 2021 today, latest insights into the progression to, and management of, heart failure were presented. Dr Carolyn Ho of Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA, discussed the results of the VANISH (Valsartan for Attenuating Disease Evolution in Early Sarcomeric HCM) trial. This trial... Read more
#ESCCongress 2021 Begins Soon!
2021 26 Aug
The ESC Congress 2021, the world’s largest cardiovascular event, begins soon. Get ready for the hottest new science in cardiology from August 27-30. During the scientific meeting, all areas of cardiovascular disease will be covered across 15 channels. The spotlight this year will be on Sudden Cardiac Death. In addition, the congress will feature... Read more